Big Pharma Deals Send Dow Lower

Merck and Pfizer held back the Dow today. Mergers and acquisitions are impacting both companies.

May 2, 2014 at 3:30PM

On a day when the Department of Labor issued a seemingly great jobs report, the Dow Jones Industrial Average (DJINDICES:^DJI) was off 0.28% late in trading. A big reason is the index's two big pharma companies, Merck (NYSE:MRK) and Pfizer (NYSE:PFE), falling as acquisition and sale rumors swirl.

The U.S. economy added 288,000 jobs in April, the most since January 2012. Unemployment fell to 6.3% as the labor force shrank by 806,000 people, a surprise number that should be taken with a grain of salt. Over the long term, the labor force will shrink as workers retire and there are fewer young people to replace them in the labor force. Still, that's a huge number and there's probably a lot of seasonality after a long winter.

Overall, more jobs is good for the economy and that should be the takeaway today.

Big Pharma holding back the Dow
Merck was the biggest Dow decliner today, falling 2.5% as of 3:30 p.m. EDT. The company is ending its trial for an ovarian cancer treatment it was testing with Endocyte after the drug failed to meet the companies' efficacy goals. The independent Data Safety Monitoring Board recommended that they stop the trial, and Merck will take on manufacturing costs related to the drug. In the grand scheme, this isn't a deal breaker for Merck, but it's a disappointing result nonetheless.  

There are also reports that Merck is near a $14 billion deal to sell its consumer unit to Bayer. Management has said it wants to sell some assets to increase operating leverage, and peeling off the consumer business will be a piece of that.  


Pfizer's headquarters will be busy with the AstraZeneca bid and may not be headquarters for long.

Elsewhere in pharma deal-making circles, AstraZeneca has reportedly rejected Pfizer's $106 billion acquisition billion bid. Pfizer is trying to acquire AstraZeneca's cancer treatment pipeline, and could move its headquarters to London in an effort to save on taxes as well.  

Pfizer has been pursuing the deal for months, but AstraZeneca CEO Pascal Soriot said the refreshed offer doesn't adequately pay the company for its new drug pipeline. If the AstraZeneca board doesn't change its mind, or the offer isn't increased, Pfizer could take the proposal straight to shareholders in a hostile takeover. That's a long, costly process that Pfizer wants to avoid, and the standoff is one reason shares are down 1.5% today.

This won't be a quick process, but Pfizer shareholders should hope a deal can be completed seamlessly. It would add important drugs to Pfizer's fading pipeline and save the company money on taxes. Only time will tell how this one plays out.

Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Travis Hoium has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers